Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>Fortrea's second quarter 2024 earnings elucidate a blend of progression and challenges in its trajectory as an independent pure-play Clinical Research Organization (CRO).</li>
<li>Following the spin-off from its parent company, the organization targets both growth from biotechnology firms and expanded engagements with large pharmaceutical companies.</li>
<li>CEO Tom Pike articulated Fortrea's leveraging of its robust services across various clinical trial phases and several therapeutic areas to enhance its market position, but also acknowledged uncertainties in contracting with biotech firms that have skewed the company's book-to-bill ratio below the target of 1.2, marking it at just under 1 this quarter.</li>
</ul>


Fortrea's second quarter 2024 earnings elucidate a blend of progression and challenges in its trajectory as an independent pure-play Clinical Research Organization (CRO).
Following the spin-off from its parent company, the organization targets both growth from biotechnology firms and expanded engagements with large pharmaceutical companies.
CEO Tom Pike articulated Fortrea's leveraging of its robust services across various clinical trial phases and several therapeutic areas to enhance its market position, but also acknowledged uncertainties in contracting with biotech firms that have skewed the company's book-to-bill ratio below the target of 1.2, marking it at just under 1 this quarter.


Fortrea Holdings Inc.: Are They Improving Their Strategic Positioning in Clinical Phases?

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

<ul><li>Fortrea's investment thesis remains intact with expectations of increasing margins by the end of 2025</li><li>Recent setbacks caused the stock to dip but potential for tax-free sale next summer and deal by 2026 still exists</li><li>Fortrea Holdings, Inc. is a Durham, NC based CRO specializing in running clinical trials, spun out of Labcorp in July 2023, with promising growth and value potential.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Fortrea's investment thesis remains intact with expectations of increasing margins by the end of 2025Recent setbacks caused the stock to dip but potential for tax-free sale next summer and deal by 2026 still existsFortrea Holdings, Inc. is a Durham, NC based CRO specializing in running clinical trials, spun out of Labcorp in July 2023, with promising growth and value potential.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Fortrea Holdings Inc (FTRE) - Wednesday, May 22, 2024

<ul>
<li>Fortrea's first quarter 2024 report demonstrates a mixed performance with signs of pivotal growth amidst ongoing strategic transformations and challenges post the recent company spin-off.</li>
<li>The clinical outsourcing company, while navigating complexities from the spin-off, seems to have slightly stumbled in immediately achieving some of its financial metrics but remains on track with the strategic and operational revamp aimed at long-term growth.</li>
<li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li>
</ul>


Fortrea's first quarter 2024 report demonstrates a mixed performance with signs of pivotal growth amidst ongoing strategic transformations and challenges post the recent company spin-off.
The clinical outsourcing company, while navigating complexities from the spin-off, seems to have slightly stumbled in immediately achieving some of its financial metrics but remains on track with the strategic and operational revamp aimed at long-term growth.
Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.


Fortrea Holdings Inc.: Enhanced Focus On Clinical Development Efficiency & Other Major Drivers

<ul>
<li>This is our first report on Fortrea Corporation, a renowned contract research organization (CRO).</li>
<li>The company reported its fourth quarter 2023 earnings, recording revenue growth of 1.8% year-over-year to $775.4 million.</li>
<li>CEO Tom Pike praised the company's transformation over 2023, managing to transition from a division within a larger parent company to a stand-alone entity.</li>
</ul>


This is our first report on Fortrea Corporation, a renowned contract research organization (CRO).
The company reported its fourth quarter 2023 earnings, recording revenue growth of 1.8% year-over-year to $775.4 million.
CEO Tom Pike praised the company's transformation over 2023, managing to transition from a division within a larger parent company to a stand-alone entity.


Fortrea Holdings: Refocusing As A Pure-Play CRO But Will It Pay Off?

United States

Fortrea Holdings Inc. operates as a holding company. The Company, through its subsidiaries, provides phase I through IV clinical trial management, clinical pharmacology, patient access solutions, and other enabling services. Fortrea Holdings partners with emerging and large biopharma and medical device and diagnostic companies to drive healthcare innovation throughout the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fortrea Holdings (FTRE US)

Fortrea Holdings Inc.: Are They Improving Their Strategic Positioning in Clinical Phases?

Fortrea's second quarter 2024 earnings elucidate a blend of progression and challenges in its trajectory as an independent pure-play Clinical...

Baptista Research

Fortrea Holdings Inc (FTRE) - Wednesday, May 22, 2024

Fortrea Holdings, Inc. is a Durham, NC based CRO specializing in running clinical trials, spun out of Labcorp in July 2023, with promising growth...

Value Investors Club

Fortrea Holdings Inc.: Enhanced Focus On Clinical Development Efficiency & Other Major Drivers

Fortrea's first quarter 2024 report demonstrates a mixed performance with signs of pivotal growth amidst ongoing strategic transformations and...

Baptista Research

Fortrea Holdings: Refocusing As A Pure-Play CRO But Will It Pay Off?

This is our first report on Fortrea Corporation, a renowned contract research organization (CRO). The company reported its fourth quarter 2023...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)